Hematologic Oncology

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

The antibody-drug conjugate TRPH-222 demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.

Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.

December 8, 2020 - Fixed-duration treatment with mosunetuzumab elicited high, durable, and consistent responses across numerous subgroups of patients with follicular lymphoma.

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.

December 7, 2020 — Findings from the MEDALIST trial demonstrated encouraging clinical efficacy, as well as a tolerable safety profile, with luspatercept among patients with myelodysplastic syndrome and myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.

December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.

December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

December 6, 2020 - Orca-T, a precision Treg-engineered donor product, demonstrated preventive potential for graft-versus-host disease, with less immunosuppression, compared with the standard of care in patients with high-risk hematologic malignancies who underwent hematopoietic stem cell transplantation.